Brickell Stock Executives

BBI
 Stock
  

USD 0.20  0.08  66.67%   

Brickell Biotech employes about 16 people. The company is managed by 17 executives with total tenure of roughly 127 years, averaging almost 7.0 years of service per executive having 0.94 employees per reported executive. Examination of Brickell Biotech management performance can provide insight into the company performance. Note, employee sentiment is becoming a valuable factor that investors use to determine the amount of risk that may be associated with Brickell Biotech future performance.
Continue to Trending Equities.
  
Refresh
  Garth Braun  CEO
President CEO, Director
  FranzXaver Schmidbauer  Chairman
Vice Chairman of the Supervisory Board
  Ludwig Schlosser  Chairman
Chairman of the Supervisory Board

Brickell Biotech Return on Sales

(100.1)

Share

Brickell Biotech Management Team Effectiveness

Brickell Biotech has Return on Asset of (79.41) % which means that on every $100 spent on asset, it lost $79.41. This is way below average. In the same way, it shows return on shareholders equity (ROE) of (151.7) %, meaning that it generated no profit with money invested by stockholders. Brickell Biotech management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. The current Return on Invested Capital is estimated to increase to 16.65, while Return on Investment is projected to decrease to (33.96) . Brickell Biotech Assets Non Current are most likely to decrease significantly in the upcoming years. The last year's value of Assets Non Current was reported at 117,000. The current Goodwill and Intangible Assets is estimated to increase to about 407.3 K, while Revenue to Assets are projected to decrease to 0.31.

Brickell Biotech Quarterly Total Assets

20.79 Million

Share
The current Weighted Average Shares is estimated to increase to about 86.7 M. The current Weighted Average Shares Diluted is estimated to increase to about 86.7 M

Brickell Biotech Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Brickell Biotech insiders, such as employees or executives, is commonly permitted as long as it does not rely on Brickell Biotech's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Brickell Biotech insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Brickell Biotech Benchmark Summation

Operator
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was zero with a total number of output elements of sixty-one. Brickell Biotech Price Series Subtraction is a subtraction of Brickell Biotech price series from its benchmark/peer..
.

Brickell Biotech Notable Stakeholders

A Brickell Biotech stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Brickell Biotech often face trade-offs trying to please all of them. Brickell Biotech's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Brickell Biotech's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Garth Braun - President CEO, DirectorProfile
FranzXaver Schmidbauer - Vice Chairman of the Supervisory BoardProfile
Ludwig Schlosser - Chairman of the Supervisory BoardProfile
Don Noakes - Vice President - OperationsProfile
Josh Wylie - Vice President - LandProfile
Craig Wiebe - Vice President - ExplorationProfile
William Macdonald - President DirectorProfile
Joshua Mann - Vice President - Business DevelopmentProfile
Ralph Allen - Vice President - GeoscienceProfile
Jeff Swainson - CFOProfile
Ron Schmitz - CFO, DirectorProfile
Kevin Andrus - Independent DirectorProfile
Sean Campbell - DirectorProfile
Petra Riechert - Investor Relations Contact OfficerProfile
Rupert Hackl - Member of the Supervisory BoardProfile
Rainer Hettmer - Sole Member of the Management BoardProfile
Ulrich Wiehle - Investor Relations ContactProfile

About Brickell Biotech Management Performance

The success or failure of an entity such as Brickell Biotech often depends on how effective the management is. Brickell Biotech management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Brickell management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Brickell management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Please read more on our stock advisor page.
Last ReportedProjected for 2022
Return on Investment(31.48) (33.96) 
Return on Average Assets(1.30) (1.33) 
Return on Average Equity(1.64) (1.68) 
Return on Invested Capital 15.43  16.65 
Return on Sales(97.54) (100.10) 
Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company was founded in 2009 and is headquartered in Boulder, Colorado. Brickell Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 16 people.
The data published in Brickell Biotech's official financial statements usually reflect Brickell Biotech's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Brickell Biotech. For example, before you start analyzing numbers published by Brickell accountants, it's critical to develop an understanding of what Brickell Biotech's liquidity, profitability, and earnings quality are in the context of the Pharmaceutical Products space in which it operates.
Please note, the presentation of Brickell Biotech's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Brickell Biotech's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Brickell Biotech's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Brickell Biotech. Please utilize our Beneish M Score to check the likelihood of Brickell Biotech's management to manipulate its earnings.

Brickell Biotech Workforce Analysis

Traditionally, organizations such as Brickell Biotech use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Brickell Biotech within its industry.

Brickell Biotech Manpower Efficiency

Return on Brickell Biotech Manpower

Revenue Per Employee512.5 K
Revenue Per Executive23.8 K
Net Loss Per Employee1.9 M
Net Loss Per Executive2.3 M
Working Capital Per Employee2.9 M
Working Capital Per Executive2.8 M
Today, most investors in Brickell Biotech Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Brickell Biotech's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's per employee growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Brickell Biotech per employee as a starting point in their analysis.

Per Employee

Brickell Biotech Per Employee Growth Over Time

Net Income Per Employee

(1.88 Million)

Share
Brickell Biotech Net Income Per Employee is most likely to decrease significantly in the upcoming years. The last year's value of Net Income Per Employee was reported at (1.83 Million)

Revenue Per Employee

512,522

Share
Brickell Biotech Revenue Per Employee is most likely to increase significantly in the upcoming years. The last year's value of Revenue Per Employee was reported at 475,020
Continue to Trending Equities. Note that the Brickell Biotech information on this page should be used as a complementary analysis to other Brickell Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.

Complementary Tools for Brickell Stock analysis

When running Brickell Biotech price analysis, check to measure Brickell Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brickell Biotech is operating at the current time. Most of Brickell Biotech's value examination focuses on studying past and present price action to predict the probability of Brickell Biotech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Brickell Biotech's price. Additionally, you may evaluate how the addition of Brickell Biotech to your portfolios can decrease your overall portfolio volatility.
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Is Brickell Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Brickell Biotech. If investors know Brickell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Brickell Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Brickell Biotech is measured differently than its book value, which is the value of Brickell that is recorded on the company's balance sheet. Investors also form their own opinion of Brickell Biotech's value that differs from its market value or its book value, called intrinsic value, which is Brickell Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Brickell Biotech's market value can be influenced by many factors that don't directly affect Brickell Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Brickell Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine Brickell Biotech value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Brickell Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.